ArticleWorld journal of surgical oncology2026
Association of neoadjuvant therapy with locoregional recurrence according to recurrence definitions in breast cancer: a retrospective cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of neoadjuvant therapy (NAT) on locoregional recurrence (LRR) remains controversial, particularly due to differences in recurrence definitions and the presence of competing events such as distant metastasis. This study aimed to evaluate the association between NAT and LRR using distinct recurrence definitions and appropriate analytical approaches.
methodsWe conducted a retrospective cohort study of patients with invasive breast cancer who underwent surgery at a single institution. LRR was evaluated using two definitions: Any LRR, defined as locoregional recurrence regardless of distant metastasis, and True LRR, defined as isolated locoregional recurrence without distant metastasis. Multivariable Cox regression, propensity score-based inverse probability of treatment weighting (IPTW), and competing risk analysis using the Fine-Gray model were applied.
resultsA total of 1,670 patients were included, of whom 323 received NAT and 1,347 did not. During a median follow-up of approximately 52.8 months, 79 patients (4.7%) developed Any LRR and 51 patients (3.1%) developed True LRR. NAT was observed to be associated with a higher incidence of Any LRR in multivariable analysis. Although a similar trend was observed for True LRR, the association did not consistently reach statistical significance across models. Competing risk analysis yielded similar findings for True LRR when distant metastasis was treated as a competing event.
conclusionsNAT was observed to be associated with a higher incidence of LRR in this retrospective cohort study; however, this association should be interpreted with caution due to substantial residual confounding and temporal heterogeneity. No causal relationship between NAT and LRR can be established. Instead, these findings highlight the importance of recurrence definitions and analytical approaches, including competing risk methods, in interpreting locoregional outcomes. These results should be considered hypothesis-generating and warrant further validation in well-designed studies.
Indexed as
Identifiers
42919274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.